Refine by
Anxiety Disorder Articles & Analysis
30 news found
Psychiatric drug development is a crucial aspect of mental health treatment, as it involves the development of medications that can effectively treat various psychiatric disorders such as depression, anxiety, schizophrenia, and others. The process of antipsychiatric drug development typically involves several stages, including identifying potential drug targets, ...
The formulated product is branded as Mentabinol®, which addresses various psychiatric disorders. Acute THC consumption can trigger paranoid thoughts in vulnerable individuals. ...
Amin Kassam, the CEO of Neeka, a true pioneer in novel surgical procedures, neurological disorders, and innovative health solutions, led the creation and development of the Neeka platform. ...
The PTR platform has the opportunity to be used for delivery of medications in other large markets, including anxiety (CTx-2103 in development), insomnia, depression, bipolar disorder, Parkinson’s disease, xerostomia (dry mouth), migraine, and hypothyroidism. ...
The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of Cingulate’s PTR platform into the anxiety therapeutic area. ...
The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of Cingulate’s PTR platform into the anxiety therapeutic area. ...
About Attention Deficit/Hyperactivity Disorder (ADHD) Attention Deficit/Hyperactivity Disorder (ADHD) is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. ...
With capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms, Societal CDMO will manufacture all clinical, registration, and commercial batches of Cingulate’s lead candidate CTx-1301, an investigational medication for the treatment of Attention Deficit / Hyperactivity ...
Many neurological conditions can be addressed with medications, but there is still significant unmet medical need. "Neurological disorders can be devastating to patients and their families, who are often left with few options," stated Larry Heaton, Chief Executive Officer of Flowonix Medical, Inc. ...
Key findings from the completed 30 mg cohort of the SHORELINE Study, other clinical data and health economics and outcomes research (HEOR), and patient survey data being presented include: In an analysis of patients in the 30 mg cohort of the SHORELINE Study with elevated anxiety (n=569) and without elevated anxiety (n=156), there was a mean reduction in the ...
Based on this data, we’re confident in the ability of CTx-2103 to provide patients with the opportunity for entire-day efficacy, safety, and convenience in a once-daily anxiety medication.” Anxiety disorders are the most common mental health concern in the U.S.1 An estimated 31 percent of U.S. adults experience an ...
Laviolette and his dedicated team of 13 scientists at Western University focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and addiction. www.laviolettelab.com CanaQuest has further enhanced the formulation and delivery format for maximum bioavailability. ...
Laviolette and his dedicated team of 13 scientists at Western University focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and addiction. www.laviolettelab.com CanaQuest has further enhanced the formulation and delivery format for maximum bioavailability. ...
Neurolief Ltd., a neurotechnology innovator, today announced enrollment of the first patient in its pivotal clinical study evaluating Relivion® DP for the treatment of major depressive disorder (MDD). The Relivion DP is the first non-invasive, multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders. ...
With the PTR™ technology as the foundation of our pipeline, we strive to make next-generation medicines that overcome significant unmet medical needs in billion-dollar markets.” Anxiety disorders are the most common mental health concern in the U.S.1 An estimated 31 percent of U.S. adults experience an anxiety ...
VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological ...
Inbrija further strengthens Biopas’ complete and innovative CNS portfolio now consisting of nine original treatments: for Parkinson’s disease, epilepsy, movement disorders, sialorrea, multiple sclerosis, anxiety, and sleep disorders,” said Pascal Forget, CEO of Biopas. About Acorda Therapeutics Acorda Therapeutics develops ...
Symptoms include: delusions or hallucinations involving the baby insomnia for several nights agitation irritable mood disorientation avoidance of the baby When postpartum psychosis is diagnosed the woman should be admitted to an inpatient unit and treatment with medication will be required. Anxiety, obsessive compulsive disorder and panic ...
The presentation titled, “Gut-Brain Axis: How substances produced by the microbiome may contribute to Autism Spectrum Disorder,” will be held on Saturday, April 9 from 1:00-2:00 pm PST. ...
Lormetazepam products are indicated in the short-term treatment of insomnia, in particular anxiety-induced insomnia. The agreement is the result of a close collaboration with Bayer, which will also ensure in both Countries a smooth transition of the assets without disruption in the market. ...